Melanotan II: The Tanning Peptide With More Going On Than the Name Suggests

In the 1980s researchers at the University of Arizona had a hypothesis that seemed almost too elegant to be true. Skin cancer rates were rising. The primary cause was UV radiation from sun exposure. The body already had a natural mechanism for protecting skin from UV damage through melanin production. If you could trigger that melanin production pharmacologically, without UV exposure, you might be able to give people photoprotective pigmentation without the very radiation that causes the cancer you were trying to prevent.

Victor Hruby and Mac Hadley set out to find a synthetic analogue of alpha-melanocyte stimulating hormone potent enough to achieve this. What they developed was Melanotan II, a cyclic heptapeptide that turned out to be one of the most potent melanocortin receptor agonists ever synthesised. It produced the tanning they were looking for. It also produced a range of other effects they were not entirely expecting, including appetite suppression, spontaneous erections in male subjects and a CNS profile of mood enhancement and heightened arousal that no one had predicted from a tanning compound.

The story of Melanotan II is interesting precisely because of where that broader receptor activity led. The researchers pivoted away from MT-II toward more selective compounds. Afamelanotide, which selectively targets MC1R, reached approval for erythropoietic protoporphyria. PT-141, which selectively targets MC3R and MC4R for sexual function, reached FDA approval as bremelanotide. Melanotan II itself, with its non-selective receptor activity and broader side effect profile, never achieved pharmaceutical approval in any jurisdiction. It is available as a research compound and is widely used in the research peptide community for its tanning and libido effects, with an evidence base that is better characterised than most people realise and a safety profile that requires genuinely honest discussion.

What Is Melanotan II?

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its cyclic structure provides stability against enzymatic degradation that linear peptides do not have, giving it a longer biological half-life than the natural alpha-MSH it is based on. It was developed at the University of Arizona in the 1980s and 1990s and entered Phase 1 clinical trials in the 1990s before the development programme was discontinued in favour of more selective analogues.

MT-II activates multiple melanocortin receptors with relatively low selectivity across the family. MC1R on melanocytes drives melanin production and the tanning effect. MC3R and MC4R in the brain regulate appetite, energy homeostasis, sexual arousal and inflammation. MC5R influences exocrine gland secretion, libido and skin repair. This broad receptor activation is simultaneously what makes Melanotan II produce its diverse range of effects and what creates the side effect profile that has complicated its development as a pharmaceutical agent.

How Does Melanotan II Work?

MC1R Activation and Melanin Production

The primary tanning mechanism. Melanotan II binds MC1R on melanocytes in the skin and stimulates the production of eumelanin, the brown-black pigment responsible for the protective tanning response. It tells the skin to produce more eumelanin through the same pathway that UV exposure normally activates, but without the UV radiation itself. The result is skin darkening that looks like a natural tan because it is using the same biological pathway, just with a pharmacological trigger rather than a solar one.

People with naturally darker skin and more responsive MC1R variants tend to develop deeper tans more quickly. People with very fair skin and red hair often carry MC1R variants that are less responsive to stimulation, which means their tanning response to Melanotan II is typically more modest.

MC3R and MC4R Activation: The Central Effects

This is where Melanotan II’s effects extend well beyond tanning. MC3R and MC4R are expressed centrally in the hypothalamus and brainstem and their activation produces appetite suppression, increased sexual arousal, mood enhancement and reduced anxiety. The libido and erectile effects observed in early clinical trials were sufficiently pronounced that PT-141 was developed specifically as a selective MC4R agonist to capture this application with fewer off-target effects.

MC5R and Peripheral Effects

MC5R activation contributes to exocrine gland effects, peripheral skin repair dimensions and additional libido components. The contribution of MC5R to the overall Melanotan II profile is less well characterised than the MC1R and MC4R components but adds to the breadth of effects that the compound produces.

What Does the Research Show?

The clinical research on Melanotan II is more extensive than many people realise, though its development pathway ultimately diverged toward the more selective compounds that succeeded it.

Tanning

Phase 1 and Phase 2 clinical trials conducted at the University of Arizona in the 1990s demonstrated that Melanotan II reliably and dose-dependently induced skin darkening in fair-skinned subjects without UV exposure. The tanning effect is well established and consistently replicated across the research community. Visible darkening typically begins within three to seven days of consistent dosing and peak tanning is achieved at two to four weeks. Once discontinued, the tan fades over four to eight weeks as skin cells turn over.

Sexual Function

Clinical trials in the 1990s showed that Melanotan II reliably induced erections in men with both psychogenic and organic erectile dysfunction, establishing the MC4R pathway as a viable target for sexual function enhancement. This finding directly led to the development of PT-141, which was designed to reproduce this effect more selectively and with a more manageable side effect profile. For most men seeking melanocortin peptide therapy for sexual function, PT-141 through a licensed clinic is the cleaner and lower-risk option given its approved status and more selective mechanism.

Appetite Suppression

MC3R and MC4R activation by Melanotan II produces meaningful appetite suppression through hypothalamic signalling pathways. This effect is a secondary outcome of the receptor activation rather than a primary application, but it is consistently reported and is relevant for those using Melanotan II in body composition contexts.

The Safety Considerations That Must Be Discussed Honestly

A January 2025 review in the Journal of the European Academy of Dermatology noted that while chronic MC1R activation through Melanotan II may theoretically provide photoprotection, safety has not been proven for this unlicensed drug. The authors emphasised that thorough skin examinations may lead to earlier melanoma diagnosis in Melanotan II users.

Documented serious adverse events including rhabdomyolysis and renal infarction have been reported in the literature. The association between Melanotan II use and melanocytic nevi changes, where existing moles darken, change shape or increase in number, is a documented concern that requires specific monitoring. This is not simply a theoretical risk from general melanocortin activation but a clinically observed finding in users.

The honest safety position is that Melanotan II is not approved for any indication in any jurisdiction, has documented serious adverse events in the literature, carries an incompletely characterised long-term safety profile particularly regarding melanocytic changes, and requires appropriate monitoring of existing moles by a dermatologist throughout any period of use.

Who Is Melanotan II Most Relevant For?

Given the evidence and safety picture described above, Melanotan II is most relevant for a specific and relatively narrow audience who understand its complete profile before making an informed decision.

It is most relevant for fair-skinned people who want to develop protective pigmentation without extensive UV exposure and who understand the melanocytic monitoring requirements that responsible use demands. It is relevant for those whose primary interest is the tanning effect and who have had a baseline dermatological assessment and are committed to ongoing mole monitoring throughout use.

For libido and sexual function applications, PT-141 is the more appropriate choice for most people given its approved status, more selective mechanism and better characterised safety profile. The sexual function effects of Melanotan II are real and well-documented but the cleaner option for this specific goal is PT-141, covered on its own page in this section.

Melanotan II is not appropriate for anyone with a personal or family history of melanoma or dysplastic nevi, anyone with a large number of moles or atypical mole patterns, anyone unwilling or unable to undertake regular dermatological monitoring of skin and moles throughout use, or anyone with cardiovascular concerns given the blood pressure effects the compound can produce.

Dosage and Protocol

Loading Phase:

Dose: 0.25mg daily, escalating to 0.5mg daily after the first week if well tolerated
Duration: 10 to 14 days
Purpose: Building melanin production and establishing the base tan
UV exposure: Modest UV exposure of 10 to 15 minutes three to four times per week during the loading phase accelerates the visible tanning response. Melanotan II stimulates melanin production but UV exposure activates its release to the skin surface

Maintenance Phase:

Dose: 0.5mg two to three times weekly
Purpose: Maintaining the achieved tan with reduced ongoing exposure to the compound
Duration: As required with regular breaks incorporated

Important practical notes:

Starting at 0.25mg rather than higher doses significantly reduces the nausea that is one of the most commonly reported side effects, particularly in the first week of use. Administering the dose in the evening before sleep reduces the impact of nausea and the flushing that often accompanies early doses. Building up gradually gives the body time to adjust to melanocortin receptor activation across all receptor subtypes simultaneously.

Administration: Subcutaneous injection into fatty tissue at the abdomen, upper thigh or upper arm. Rotate injection sites consistently.

Reconstitution and Mixing Guide

Melanotan II typically comes as lyophilised powder in vials of 10mg.

Using a 10mg (10,000mcg) vial as the reference:

Add 1ml of bacteriostatic water:

Concentration = 10,000mcg per ml
Each unit on a 100-unit insulin syringe = 100mcg
A 0.25mg (250mcg) dose = 2.5 units
A 0.5mg (500mcg) dose = 5 units

Add 2ml of bacteriostatic water (most commonly used ratio):

Concentration = 5,000mcg per ml
Each unit on a 100-unit insulin syringe = 50mcg
A 0.25mg (250mcg) dose = 5 units
A 0.5mg (500mcg) dose = 10 units

Add 4ml of bacteriostatic water:

Concentration = 2,500mcg per ml
Each unit on a 100-unit insulin syringe = 25mcg
A 0.25mg (250mcg) dose = 10 units
A 0.5mg (500mcg) dose = 20 units

For most people adding 2ml to a 10mg vial creates the most practical working concentration with straightforward unit calculations at both standard dose levels.

Reconstitution Method

Inject bacteriostatic water slowly down the inside wall of the vial rather than directly onto the powder. Gently swirl rather than shake until fully dissolved. The solution should be clear and colourless.

Storage

Reconstituted Melanotan II should be refrigerated at 2 to 8 degrees Celsius and protected from light, as the peptide is light-sensitive and degrades with UV exposure. Use within 28 to 30 days of reconstitution. Lyophilised powder should be stored frozen and protected from light until ready for reconstitution.

Supporting Supplements

The supplements that most coherently support Melanotan II use are those that protect skin health during a period of accelerated melanin production and manage the oxidative and cardiovascular aspects of its broader receptor activity.

Vitamin E and Vitamin C together provide antioxidant protection for melanocytes during accelerated melanin production. The melanin synthesis process itself generates reactive oxygen species as a byproduct, and adequate antioxidant support reduces the oxidative burden on melanocytes during active tanning.

Omega-3 fatty acids support the skin barrier integrity and anti-inflammatory environment that healthy skin requires during any protocol involving hormonal signalling changes at the skin level.

Zinc supports skin health, immune function and the wound healing dimensions of MC5R-related skin repair effects.

Astaxanthin provides specific carotenoid antioxidant protection relevant to skin and melanocyte health, with particular relevance to anyone using Melanotan II specifically for photoprotection given its own independent UV protective properties.

Magnesium supports cardiovascular function and blood pressure regulation, relevant to the blood pressure effects that Melanotan II can produce through its central and peripheral receptor activation.

Foods That Complement Melanotan II

The nutritional approach during Melanotan II use focuses on supporting melanocyte health, skin antioxidant protection and the overall skin condition that determines how well the tanning response develops and maintains.

Foods rich in beta-carotene and lycopene, including carrots, sweet potato, tomatoes and red peppers, support skin pigmentation health and provide natural carotenoid photoprotection that complements the melanin-based protection Melanotan II is stimulating.

Oily fish delivers the omega-3 fatty acids that support skin barrier integrity and the anti-inflammatory environment in which melanocyte activity and skin health are best maintained.

Dark chocolate with high cocoa content delivers flavanols that support cutaneous blood flow and skin health during active melanin production.

Leafy green vegetables provide the broad micronutrient spectrum that skin health requires, including Vitamin K, folate and the antioxidants that protect newly produced melanin from oxidative degradation.

Alcohol is worth minimising during Melanotan II use given its vasodilatory effects that can compound the flushing that Melanotan II itself produces, and its negative effects on skin quality and hydration.

Lifestyle Considerations

Dermatological monitoring is not a recommendation but a requirement for responsible Melanotan II use. A baseline skin and mole assessment before starting and regular monitoring throughout is the minimum responsible approach given the documented melanocytic changes associated with Melanotan II use. Any new moles, rapid changes to existing moles or unusual skin changes during use should be assessed promptly by a dermatologist.

Sun protection alongside Melanotan II requires specific thought. The compound stimulates melanin production and the intent for some users is to develop protective pigmentation that allows modest sun exposure more safely. However Melanotan II does not provide instant photoprotection and sun protection measures remain important throughout use, particularly in the early loading phase before meaningful melanin has been produced.

Cardiovascular monitoring is worth specific consideration given Melanotan II’s effects on blood pressure. Those with existing cardiovascular concerns should approach this compound with professional guidance and should monitor blood pressure throughout use.

Managing nausea in the early days of use through evening dosing, starting at the lowest effective dose and ensuring the stomach is not completely empty at injection time are the most effective practical strategies for the most consistently reported side effect.

Compound Pairing

PT-141 is sometimes discussed alongside Melanotan II for those who want to separate the tanning and sexual function applications. PT-141’s selective MC4R activity produces the sexual arousal effects with considerably less tanning, nausea and cardiovascular activity than Melanotan II. For most people the cleaner approach is to use PT-141 specifically for sexual function and to consider Melanotan II separately only if tanning is a primary goal.

GHK-Cu complements Melanotan II for skin health through its collagen synthesis, gene expression and skin repair mechanisms that support the overall dermal environment in which melanocyte activity is occurring.

BPC-157 provides gut protective support that is particularly relevant for those experiencing significant nausea in the early stages of Melanotan II loading, given BPC-157’s well-established gastroprotective and gut-lining supportive effects.

Realistic Expectations

Melanotan II produces the tanning effect it is used for consistently and reliably in the people for whom it works. Visible darkening typically begins within three to seven days of consistent loading. A full tan effect is typically achieved within two to four weeks with modest UV exposure alongside dosing. The tan looks natural because it uses the same biological pathway as sun-induced tanning.

The side effects are real and require honest acknowledgment. Nausea in the early loading phase is the most commonly reported and most reliably predictable. Flushing and facial redness following injection are common. Spontaneous erections in men are reported at standard doses. Blood pressure changes require awareness and monitoring. Mole darkening and changes are documented and require dermatological oversight.

Melanotan II is not approved for any use anywhere in the world. It carries documented serious adverse events in the literature. It has an incompletely characterised long-term safety profile. These are not reasons to dismiss it as a compound with no legitimate research interest, but they are reasons to engage with it with complete honesty, appropriate monitoring and a clear understanding of what is and is not established about its safety.

For those who make an informed decision to use it with appropriate monitoring, realistic dose escalation and ongoing dermatological oversight, Melanotan II delivers the tanning effect that has made it one of the most discussed compounds in the research peptide community for three decades.